To hear about similar clinical trials, please enter your email below
Trial Title:
Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
NCT ID:
NCT06624319
Condition:
Post Operative Pain
Conditions: Official terms:
Pain, Postoperative
Dexmedetomidine
Conditions: Keywords:
Tap block
Dexmedetomidine
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
Patients will receive pre-emptive ultrasound-guided tap block with two different doses of
dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20
ml will be applied on each side of the abdominal wall after induction of GA.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Dexmedetomidine as adjuvent to bupvacaine in tap block
Description:
The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine
in tap block
Arm group label:
tap block with 0.5 μg/kg dexmedetomidine
Arm group label:
tap block with 1.5 μg/kg dexmedetomidine
Other name:
Precedex
Summary:
The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to
bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower
abdominal cancer surgeries.
Detailed description:
The transversus abdominis plane (TAP) involves innervations of the anterolateral
abdominal wall derived from T6-L1. The block can be given either by anatomical landmark
technique or by using an ultrasound probe. The local anesthetic is deposited in a plane
between internal oblique and transversus abdominis muscle. It provides adequate
postoperative analgesia following various abdominal surgeries.Dexmedetomidine is an
alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain
relief .In previous studies, the addition of dexmedetomidine to bupivacaine in the TAP
block has prolonged the effect of this block . So far, the optimal dose of
dexmedetomidine for the TAP block has not been determined.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- age from 18 to 65 years old
- lower abdominal cancer surgery
Exclusion Criteria:
- patient refusal
- the local anesthetic allergy
- coagulopathy
- local infection at the procedure site
- psychic patients
- patient on chronic opioid use
Gender:
All
Minimum age:
18 Years
Maximum age:
65 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
South egypt cancer institute,Assiut University
Address:
City:
Assiut
Country:
Egypt
Contact:
Last name:
Kerolos S Tawfeek, Resident
Phone:
01551990411
Email:
Kerolossalama7@gmail.com
Contact backup:
Last name:
Mohanad A Mohamed, Lecturer
Phone:
01027068866
Email:
Mohanad.abosagheer@gmail.com
Start date:
January 2025
Completion date:
February 2026
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06624319
